| |
Private for-profit facility % CI
|
Pharmacy % CI
|
ADDO % CI
|
DLDB % CI
|
Private sector total % CI
|
|---|
|
N=118
|
N=60
|
N=1468
|
N=142
|
N=1800
|
|---|
|
QA ACT
|
73.6 (63.0, 82.0)
|
90.0 (75.0, 96.4)
|
66.3 (57.7, 74.0)
|
58.8 (42.8, 73.1)
|
65.1 (57.2, 72.3)
|
|
Non-QA ACT
|
66.5 (49.0, 80.4)
|
98.7 (94.2, 99.7)
|
43.3 (33.1, 54.1)
|
34.9 (21.3, 51.4)
|
42.9 (31.5, 55.1)
|
|
SP
|
76.8 (70.0, 82.4)
|
94.4 (90.2, 96.9)
|
92.2 (87.9, 95.0)
|
75.2 (62.2, 84.9)
|
86.3 (80.4, 90.6)
|
|
Oral quinine
|
63.9 (49.0, 76.6)
|
74.8 (61.7, 84.5)
|
65.2 (57.7, 72.1)
|
67.8 (51.5, 80.6)
|
64.6 (57.9, 70.8)
|
|
Other non-artemisinin therapy
|
8.1 (3.9, 16.2)
|
0.7 (0.1, 3.4)
|
2.6 (1.3, 5.3)
|
6.1 (2.6, 14.0)
|
4.0 (2.3, 7.0)
|
|
IV/IM artesunate
|
34.4 (26.9, 42.9)
|
17.9 (5.6, 44.5)
|
0.2 (0.1, 0.8)
|
0.0 (–)
|
2.4 (1.4, 4.0)
|
| |
N=120
|
N=61
|
N=1490
|
N=146
|
N=1832
|
|---|
|
Any test
|
96.0 (91.1, 98.3)
|
21.9 (12.8, 34.8)
|
10.2 (6.4, 15.9)
|
8.1 (3.9, 16.2)
|
15.7 (12.6, 19.4)
|
|
Microscopy
|
73.9 (51.0, 88.5)
|
8.8 (1.8, 34.3)
|
0.6 (0.2, 2.3)
|
0.0 (–)
|
5.4 (2.8, 10.3)
|
|
RDT
|
78.5 (69.4, 85.4)
|
21.9 (12.8, 34.8)
|
9.7 (6.0, 15.3)
|
8.1 (3.9, 16.2)
|
14.3 (11.4, 17.7)
|
